Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Can efavirenz be taken in the morning?
Skeie L, Maeland A. Skeie L, et al. Among authors: maeland a. Scand J Infect Dis. 2006;38(11-12):1089-91. doi: 10.1080/00365540600794386. Scand J Infect Dis. 2006. PMID: 17148083 Clinical Trial.
[HIV/AIDS--from lethal syndrome to chronic disease].
Bruun JN, Skeie L, Maeland A, Dudman SG, Sannes M, Ormaasen V. Bruun JN, et al. Among authors: maeland a. Tidsskr Nor Laegeforen. 2006 Nov 30;126(23):3121-4. Tidsskr Nor Laegeforen. 2006. PMID: 17160119 Free article. Norwegian.
Antiretroviral treatment initiation.
Maeland A. Maeland A. Lancet Infect Dis. 2014 Dec;14(12):1175. doi: 10.1016/S1473-3099(14)70947-8. Epub 2014 Nov 17. Lancet Infect Dis. 2014. PMID: 25455976 No abstract available.
Genotype, viral load and age as independent predictors of treatment outcome of interferon-alpha 2a treatment in patients with chronic hepatitis C. Construct group.
Bell H, Hellum K, Harthug S, Maeland A, Ritland S, Myrvang B, von der Lippe B, Raknerud N, Skaug K, Gutigard BG, Skjaerven R, Prescott LE, Simmonds P. Bell H, et al. Among authors: maeland a. Scand J Infect Dis. 1997;29(1):17-22. doi: 10.3109/00365549709008658. Scand J Infect Dis. 1997. PMID: 9112292 Clinical Trial.
Two dose regimens of recombinant interferon-alpha-2b in chronic hepatitis C virus infection. Biochemistry, hepatitis C virus RNA, and liver histology as response indices.
Bjøro K, Krarup H, Bell H, Christophersen P, Evensen S, Frøland SS, Laursen A, B vd Lippe B, Maeland A, Ranek L, et al. Bjøro K, et al. Among authors: maeland a. Scand J Gastroenterol. 1995 Nov;30(11):1119-24. doi: 10.3109/00365529509101617. Scand J Gastroenterol. 1995. PMID: 8578174 Clinical Trial.
Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group.
Bell H, Hellum K, Harthug S, Myrvang B, Ritland S, Maeland A, von der Lippe B, Bjøro K, Skaug K, Gutigard BG, Raknerud N, Simmonds P. Bell H, et al. Among authors: maeland a. Scand J Gastroenterol. 1999 Feb;34(2):194-8. doi: 10.1080/00365529950173087. Scand J Gastroenterol. 1999. PMID: 10192200 Clinical Trial.
Interferon-alpha 2b therapy in low-activity hepatitis C: a pilot study.
Nordøy I, Krarup HB, Bell H, Christensen PB, Elgjo K, von der Lippe B, De Muckadell OS, Maeland A, Ring-Larsen H, Samdal HH, Simmonds P, Skaug K, Tage-Jensen U, Schrumpf E. Nordøy I, et al. Among authors: maeland a. Scand J Gastroenterol. 1997 Dec;32(12):1256-60. doi: 10.3109/00365529709028156. Scand J Gastroenterol. 1997. PMID: 9438325 Clinical Trial.
112 results